A gain-of-function variant in the Wiskott-Aldrich syndrome gene is associated with a MYH9-related disease-like syndrome.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
27 09 2022
27 09 2022
Historique:
received:
15
12
2021
accepted:
27
03
2022
pubmed:
12
4
2022
medline:
23
9
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
While loss-of-function variants in the WAS gene are associated with Wiskott-Aldrich syndrome and lead to microthrombocytopenia, gain-of-function variants of WAS are associated with X-linked neutropenia (XLN) and the absence of microthrombocytopenia. Only a few XLN families have been reported so far, and their platelet phenotype was not described in detail. To date, no renal involvement was described in XLN. In the present study, we report exome sequencing of individuals from 3 generations of a family with a dominant disease combining neutropenia, macrothrombocytopenia, and renal failure. We identified a heterozygous missense gain-of-function variant in the WAS gene (c.881T>C, p.I294T) that segregates with the disease and is already known to cause XLN. There was no pathogenic variant in MYH9, TUBB1, or ACTN1. This is the first report of a WAS gain-of-function variant associated with both the hematological phenotype of XLN (neutropenia, macrothrombocytopenia) and renal disease (proteinuria, renal failure) with glomerular tip lesion hyalinosis and actin condensations in effaced podocytes foot processes.
Identifiants
pubmed: 35404999
pii: 484679
doi: 10.1182/bloodadvances.2021006789
pmc: PMC9631694
doi:
Substances chimiques
Actins
0
MYH9 protein, human
0
Wiskott-Aldrich Syndrome Protein
0
Myosin Heavy Chains
EC 3.6.4.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5279-5284Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
J Clin Invest. 2018 Aug 31;128(9):4115-4131
pubmed: 30124469
J Hum Genet. 2019 Jul;64(7):689-694
pubmed: 31068678
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Am J Hum Genet. 2013 May 2;92(5):681-95
pubmed: 23623388
Pediatrics. 2003 May;111(5 Pt 1):e622-7
pubmed: 12728121
Br J Haematol. 2009 Jan;144(1):120-6
pubmed: 19006568
Methods Mol Biol. 2004;272:13-28
pubmed: 15226531
Blood. 2014 Feb 20;123(8):1261-9
pubmed: 24243973
Hum Genet. 2005 Feb;116(3):222-4
pubmed: 15565283
Child Nephrol Urol. 1988-1989;9(1-2):118-20
pubmed: 3251617
Blood. 2006 Oct 1;108(7):2182-9
pubmed: 16804117
Semin Thromb Hemost. 2009 Mar;35(2):189-203
pubmed: 19408192
J Am Soc Nephrol. 2013 Apr;24(5):713-21
pubmed: 23471198
Blood. 2004 Jan 15;103(2):456-64
pubmed: 12969986
Nat Rev Immunol. 2010 Mar;10(3):182-92
pubmed: 20182458
Gene. 2018 Jul 20;664:152-167
pubmed: 29679756
Kidney Int. 2010 Jul;78(2):207-14
pubmed: 20200500
Clin Immunol. 2012 Feb;142(2):160-6
pubmed: 22079330
Ann N Y Acad Sci. 2013 May;1285:26-43
pubmed: 23527602
Am J Kidney Dis. 2004 Feb;43(2):368-82
pubmed: 14750104
Ann Allergy. 1984 Jul;53(1):74-8
pubmed: 6377982
Nat Genet. 2001 Mar;27(3):313-7
pubmed: 11242115
Nat Genet. 2004 Jun;36(6):597-601
pubmed: 15122253
Ann Hematol. 2018 Feb;97(2):367-369
pubmed: 28956125
J Exp Med. 2010 Jun 7;207(6):1145-52
pubmed: 20513746
Am J Hum Genet. 1997 Dec;61(6):1353-61
pubmed: 9399909
J Cell Biol. 2006 Apr 10;173(1):121-32
pubmed: 16606694